Agenus/$AGEN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Agenus
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
- Ticker
- $AGEN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 81
- Headquarters
- Lexington, United States
- Website
- www.agenusbio.com
Agenus Metrics
BasicAdvanced
$327M
16.80
$0.43
1.52
-
Price and volume
Market cap
$327M
Beta
1.52
52-week high
$10.31
52-week low
$2.71
Average daily volume
862K
Financial strength
Current ratio
0.728
Quick ratio
0.705
Long term debt to equity
-0.296
Total debt to equity
-0.352
Interest coverage (TTM)
0.86%
Profitability
EBITDA (TTM)
54.362
Gross margin (TTM)
122.88%
Net profit margin (TTM)
30.77%
Operating margin (TTM)
38.94%
Revenue per employee (TTM)
$1,650,000
Management effectiveness
Return on assets (TTM)
13.60%
Return on equity (TTM)
-20.93%
Valuation
Price to earnings (TTM)
16.797
Price to revenue (TTM)
2.38
Price to book
-3.1
Price to tangible book (TTM)
-2.47
Price to free cash flow (TTM)
-3.069
Free cash flow yield (TTM)
-32.59%
Free cash flow per share (TTM)
-2.353
Growth
Revenue change (TTM)
25.38%
Earnings per share change (TTM)
-132.64%
3-year revenue growth (CAGR)
9.90%
10-year revenue growth (CAGR)
18.45%
3-year earnings per share growth (CAGR)
-70.06%
10-year earnings per share growth (CAGR)
-33.90%
What the Analysts think about Agenus
Analyst ratings (Buy, Hold, Sell) for Agenus stock.
Analyst projections of the future price of Agenus stock.
Bulls say / Bears say
A peer-reviewed Phase 2 NEST update found a major pathologic response in 41% and a complete response in 32% of 22 MSS tumours, with no recurrences reported at the latest follow-up. This gives the planned ROBBIN Phase 3 trial a promising clinical rationale in a large, underserved group, though the results still need confirmation in a controlled trial. (Agenus)
Armenia granted the first marketing authorisations for BOT and BAL in previously treated MSS metastatic colorectal cancer, creating an initial route to treatment outside trials. The approvals are conditional and limited to Armenia for now, but they mark regulatory progress for the combination. (Agenus)
In a heavily pretreated MSS metastatic colorectal cancer cohort, BOT+BAL showed median overall survival of 21.2 months and 33% three-year survival; 17% of patients were alive and off systemic treatment at last follow-up. These durable outcomes support the drug combination’s potential in a difficult-to-treat setting. (Agenus)
Agenus said its upfront financing should fund operations only into the third quarter of 2027, and further development will require additional capital; its filing also disclosed substantial doubt about its ability to continue as a going concern. The further $255 million from warrants is not assured, while the share and warrant issuance creates material dilution risk. (SEC)
The NEST evidence is from a single-centre, open-label Phase 2 study, with only 22 MSS tumours assessed, so it cannot establish that BOT+BAL improves outcomes versus standard care. The planned Phase 3 ROBBIN trial is expected to begin in 2027, leaving the central efficacy claim unproven for now. (Agenus, Agenus)
Agenus withdrew its funding support for the Phase 3 BATTMAN trial in late-line metastatic MSS colorectal cancer, after which the study was terminated. This removes another potential development route and concentrates the investment case more heavily on the still-unproven neoadjuvant ROBBIN programme. (Agenus)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
Agenus Financial Performance
Revenues and expenses
Agenus Earnings Performance
Company profitability
Upcoming events
No upcoming events
Agenus News
AllArticlesVideos
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
Business Wire6 days ago
Agenus Targets Phase 3 Colon Cancer Trial as Financing Hinges on Enrollment Milestones
MarketBeat1 week ago
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
Business Wire1 week ago
Funds containing Agenus
Fund name | Fund size | $AGEN weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.